GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » Cyclically Adjusted Price-to-FCF

Soligenix (STU:DOA) Cyclically Adjusted Price-to-FCF : (As of May. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Soligenix Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Soligenix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Soligenix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Cyclically Adjusted Price-to-FCF Chart

Soligenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Soligenix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Soligenix's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Soligenix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soligenix's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Soligenix's Cyclically Adjusted Price-to-FCF falls into.



Soligenix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Soligenix's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Soligenix's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.119/131.7762*131.7762
=-0.119

Current CPI (Mar. 2024) = 131.7762.

Soligenix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -4.060 100.560 -5.320
201409 -5.638 100.428 -7.398
201412 -1.330 99.070 -1.769
201503 -8.607 99.621 -11.385
201506 -11.459 100.684 -14.998
201509 -1.614 100.392 -2.119
201512 -6.663 99.792 -8.799
201603 -2.659 100.470 -3.488
201606 -7.009 101.688 -9.083
201609 -4.690 101.861 -6.067
201612 -4.727 101.863 -6.115
201703 -4.173 102.862 -5.346
201706 -3.228 103.349 -4.116
201709 -2.651 104.136 -3.355
201712 -3.797 104.011 -4.811
201803 -2.036 105.290 -2.548
201806 -3.146 106.317 -3.899
201809 -0.712 106.507 -0.881
201812 -1.990 105.998 -2.474
201903 -1.684 107.251 -2.069
201906 -0.371 108.070 -0.452
201909 -1.395 108.329 -1.697
201912 -1.709 108.420 -2.077
202003 -1.567 108.902 -1.896
202006 -0.814 108.767 -0.986
202009 -1.288 109.815 -1.546
202012 -1.694 109.897 -2.031
202103 -1.363 111.754 -1.607
202106 -0.515 114.631 -0.592
202109 -0.952 115.734 -1.084
202112 -0.668 117.630 -0.748
202203 -1.031 121.301 -1.120
202206 -0.835 125.017 -0.880
202209 -1.145 125.227 -1.205
202212 -1.187 125.222 -1.249
202303 -0.694 127.348 -0.718
202306 -0.245 128.729 -0.251
202309 -0.242 129.860 -0.246
202312 -0.161 129.419 -0.164
202403 -0.119 131.776 -0.119

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Soligenix  (STU:DOA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Soligenix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Soligenix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Soligenix (STU:DOA) Business Description

Industry
Traded in Other Exchanges
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix (STU:DOA) Headlines

No Headlines